This Institute performed research into protection against exposure to Soman (GD) in the late 1980s and early 1990s. This work appears to have ended after 1993.

Sources:
[1] Z. Grubic, M. Brank, M. Brzin, "The effects of pretreatment with soman simulator in the skeletal muscle: direct interactions with acetylcholinesterase," Chemico-biological interactions 87 (1-3) (June 1993), pp. 253-257;
[2] M. Brank, M. Sentjurc, A. Stalc, and Z. Grubic, "The influence of soman simulator on reactivation by HI-6 of soman-inhibited acetylcholinesterase in preparations of rat and human skeletal muscle," Biochemical Pharmacology 45 (2) (January 1993), pp. 499-508;
[3] D. Sket, "Efficacy of antidotes against soman poisoning in female physostigmine-protected rats," Pharmacology & toxicology 72 (1) (January 1993), pp. 25-30;
[4] A. Dekleva, D. Sket, J. Sketelj, M. Brzin, "Attenuation of soman-induced lesions of skeletal muscle by acetylcholinesterase reactivating and non-reactivating antidotes," Acta neuropathologica (Berlin) 79 (2) (1989), pp. 183-189;
[5] D. Sket, M. Brzin, "Effect of HI-6, applied into the cerebral ventricles, on the inhibition of brain acetylcholinesterase by soman in rats," Neuropharmacology 25 (1) (January 1986), pp.103-107.